Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

558.87
+13.412.46%
Post-market: 562.994.12+0.74%19:55 EDT
Volume:1.66M
Turnover:920.76M
Market Cap:60.34B
PE:14.17
High:583.28
Open:583.01
Low:542.89
Close:545.46
Loading ...

Regeneron Pharmaceuticals Launches Long-Term Follow-Up Study on Gene Modified T Cell Therapy

TIPRANKS
·
12 Jul

UBS Raises Price Target on Regeneron Pharmaceuticals to $584 From $560, Keeps Neutral Rating

MT Newswires Live
·
11 Jul

US judge won't block 23andMe bankruptcy sale to co-founder

Reuters
·
11 Jul

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
11 Jul

Regeneron Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
11 Jul

Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $754 From $755, Maintains Overweight Rating

MT Newswires Live
·
10 Jul

Maia Biotechnology Inc. Expands Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer with First Patient Dosed in Taiwan

Reuters
·
09 Jul

Regeneron's Blockbuster Dupixent Faces a New Rival -- Barrons.com

Dow Jones
·
09 Jul

Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), Regeneron (REGN)

TIPRANKS
·
08 Jul

California fails to stop 23andMe founder from re-acquiring company

Reuters
·
08 Jul

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
08 Jul

Regeneron (REGN) Gets a Hold from RBC Capital

TIPRANKS
·
08 Jul

RBC Raises Price Target on Regeneron Pharmaceuticals to $688 From $662, Keeps Sector Perform Rating

MT Newswires Live
·
07 Jul

BUZZ-Apogee Therapeutics jumps after eczema drug meets main goal in mid-stage study

Reuters
·
07 Jul

TD Cowen Remains a Buy on Regeneron (REGN)

TIPRANKS
·
03 Jul

Regeneron (REGN) Receives a Buy from Citi

TIPRANKS
·
03 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos Financial

Reuters
·
03 Jul

BRIEF-Regeneron Says Wholesale Acquisition Cost For Lynozyfic Is $470.00 Per 5 Mg Vial

Reuters
·
03 Jul

US FDA approves Regeneron's blood cancer therapy

Reuters
·
02 Jul

Regeneron Pharmaceuticals Secures FDA Accelerated Approval for Lynozyfic™ in Treating Relapsed or Refractory Multiple Myeloma

Reuters
·
02 Jul